Literature DB >> 10732975

3-Aryl-2-carbomethoxybicyclo[3.2.1]oct-2-enes inhibit WIN 35,428 binding potently and selectively at the dopamine transporter.

P C Meltzer1, P Blundell, H Huang, S Liu, Y F Yong, B K Madras.   

Abstract

The search for medications for cocaine abuse has focused upon the design of potential cocaine antagonists or cocaine substitutes which interact at the dopamine transporter of mammalian systems. This manuscript describes the synthesis and biological evaluation of 8-substituted 2-carbomethoxy-3-arylbicyclo[3.2.1]oct-2-enes. These compounds prove potent and selective inhibitors of the dopamine transporter. Their selectivity results primarily from a reduced inhibitory potency toward the serotonin transporter. This work supports the notion that the orientation of the 3-aryl ring in the bicyclo[3.2.1]octane system affects the interaction of these molecules with the serotonin transporter far more markedly than it affects the interaction with the dopamine transporter.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10732975     DOI: 10.1016/s0968-0896(99)00322-3

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Synthesis and structure-activity relationship studies of 3-biaryl-8-oxabicyclo[3.2.1]octane-2-carboxylic acid methyl esters.

Authors:  Lokman Torun; Bertha K Madras; Peter C Meltzer
Journal:  Bioorg Med Chem       Date:  2012-02-08       Impact factor: 3.641

2.  Synthesis of highly functionalised enantiopure bicyclo[3.2.1]- octane systems from carvone.

Authors:  Antonio Abad; Consuelo Agulló; Ana C Cuñat; Ignacio de Alfonso; Ismael Navarro; Noelia Vera
Journal:  Molecules       Date:  2004-04-30       Impact factor: 4.411

3.  The synthesis of bivalent 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)-8-heterobicyclo[3.2.1]octanes as probes for proximal binding sites on the dopamine and serotonin transporters.

Authors:  Peter C Meltzer; Olga Kryatova; Duy-Phong Pham-Huu; Patrick Donovan; Aaron Janowsky
Journal:  Bioorg Med Chem       Date:  2007-11-06       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.